Search

Amphastar Pharmaceuticals Inc

Отворен

СекторЗдравеопазване

20.93 4.08

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

19.82

Максимум

21.03

Ключови измерители

By Trading Economics

Приходи

24M

30M

Продажби

13M

184M

P/E

Средно за сектора

12.309

57.002

EPS

0.8

Марж на печалбата

16.502

Служители

1,976

EBITDA

12M

45M

Препоръки

By TipRanks

Препоръки

Неутрален

12-месечна прогноза

+7.38% upside

Дивиденти

By Acuity

Следващи печалби

5.11.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

18M

864M

Предишно отваряне

16.85

Предишно затваряне

20.93

Настроения в новините

By Acuity

84%

16%

319 / 340 Класиране в Healthcare

Amphastar Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

12.08.2026 г., 20:06 ч. UTC

Amphastar Pharmaceuticals Inc shares are lower in Wednesday's session, continuing a decline from Tuesday's close amid fluctuating U.S. Treasury yields and inflation data.

11.08.2026 г., 19:56 ч. UTC

News

Amphastar Pharmaceuticals reported Q2 revenue of $183.9 million, exceeding expectations. Shares are modestly higher amid strong demand for key products and new launches.

10.08.2026 г., 19:36 ч. UTC

News

Amphastar Pharmaceuticals reported Q2 earnings of $0.70 per share on $183.9 million in revenue, but shares are trading lower today amid a slight net income decline.

7.08.2026 г., 19:51 ч. UTC

News

Amphastar Pharmaceuticals reported Q2 EPS of $0.91, exceeding estimates. Revenue also surpassed expectations, contributing to a positive market response and higher shares.

6.08.2026 г., 23:02 ч. UTC

News

Amphastar Pharmaceuticals reported second-quarter sales of $183.9 million, exceeding expectations. Shares are trading higher in after-market hours following the strong results.

4.08.2026 г., 19:51 ч. UTC

Amphastar Pharmaceuticals is trading lower today, breaking a trend of higher daily closes. No specific news was identified to explain the decline.

3.08.2026 г., 19:46 ч. UTC

Amphastar Pharmaceuticals Inc is trading higher, reaching a session high amid positive market conditions and falling oil prices influencing investor sentiment.

31.07.2026 г., 19:36 ч. UTC

Amphastar Pharmaceuticals is declining today, continuing a downward trend since Thursday. The stock reached a session low earlier this morning amid broader market volatility.

30.07.2026 г., 19:28 ч. UTC

Amphastar Pharmaceuticals Inc. shares are lower amid significant downward pressure in the Pharmaceuticals sub-sector, reflecting broader sector weakness during Thursday's session.

29.07.2026 г., 20:41 ч. UTC

Amphastar Pharmaceuticals shares are lower in after-market trading, continuing a decline amid rising crude oil prices and geopolitical tensions in the Middle East.

28.07.2026 г., 20:02 ч. UTC

Amphastar Pharmaceuticals shares are higher today, diverging from a broader market decline amid a sell-off in technology stocks across Asian markets.

24.07.2026 г., 19:06 ч. UTC

Amphastar Pharmaceuticals is trading higher, supported by a pullback in crude oil prices, which has eased some inflationary pressures affecting investor sentiment.

22.07.2026 г., 20:06 ч. UTC

Amphastar Pharmaceuticals Inc shares are lower today, continuing a four-session decline amid market uncertainty ahead of the Federal Reserve meeting on July 29.

21.07.2026 г., 19:46 ч. UTC

Amphastar Pharmaceuticals Inc is trading lower, continuing a three-session decline. No specific news was identified to explain the stock's performance.

20.07.2026 г., 19:56 ч. UTC

Amphastar Pharmaceuticals is gaining modestly during Monday's session amid mixed market conditions and geopolitical tensions affecting oil prices and inflation concerns.

Сравнение с други в отрасъла

Ценова промяна

Amphastar Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

7.38% нагоре

12-месечна прогноза

Среден 21.67 USD  7.38%

Висок 30 USD

Нисък 20 USD

Според 6 анализатори от Wall Street, предложили 12-месечна ценова цел за Amphastar Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

6 ratings

0

Купи

5

Задържане

1

Продай

Настроение

By Acuity

319 / 340 Класиране в Здравеопазване

Настроения в новините

Много силни мечи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Amphastar Pharmaceuticals Inc

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
help-icon Live chat